Is Hypercortisolism Treatable? Which Patients Should Be Treated and How—A Practical Guide for Clinicians Authors: Juan Pablo Frias Published: 2026 ABSTRACT ABSTRACTAimTo provide a practical guide on when to suspect endogenous hypercortisolism, how to use the overnight 1‐mg dexamethasone suppression test (DST) for targeted case‐finding, and which patients are most likely to benefit from treatment.Materials and MethodsThis narrative review synthesizes evidence from clinical practice guidelines, prospective prevalence studies, randomized controlled trials, systematic reviews, and meta‐analyses addressing the recognition, diagnosis, and management of endogenous hypercortisolism in patients with treatment‐resistant type 2 diabetes (T2D), resistant hypertension, and adrenal incidentalomas.ResultsConfirmed endogenous hypercortisolism is found in 0.6%‐3.4% of broader T2D cohorts after stepwise biochemical evaluation, but recent prospective studies—including CATALYST and MOMENTUM—report abnormal cortisol suppression in approximately one in four patients within selected high‐risk groups. Mild autonomous cortisol secretion (MACS), defined as ACTH‐independent cortisol production with post‐dexamethasone serum cortisol > 50 nmol/L (> 1.8 μg/dL) in the absence of classic Cushingoid features, is associated with clinically meaningful increases in hypertension, T2D, visceral adiposity, and all‐cause mortality. Routine screening of all patients with diabetes or hypertension is not recommended; testing should be reserved for those with multiple, progressive, or atypical cardiometabolic features, or with adrenal incidentalomas. Attention to test timing, drug interactions, and physiologic non‐neoplastic hypercortisolism is essential for accurate interpretation. When etiology and laterality permit, surgical resection offers the best chance for durable remission. When surgery is not feasible, not curative, or declined, medical alternatives—including glucocorticoid‐receptor antagonists (e.g., mifepristone) and steroidogenesis inhibitors (e.g., osilodrostat, ketoconazole)—can reduce cortisol activity or lower cortisol production, each with specific efficacy, tolerability, and safety considerations warranting endocrinologist involvement.ConclusionAs cortisol activity falls, glucose‐ and blood‐pressure medications often require down‐titration. Monitoring for adrenal insufficiency, cortisol withdrawal syndrome, and drug‐specific adverse effects requires coordinated multidisciplinary follow‐up. Through careful evaluation and targeted treatment, hypercortisolism can be recognized and managed as a modifiable contributor to cardiometabolic risk.Keywords: dexamethasone suppression test, hypercortisolism, mild autonomous cortisol secretion, resistant hypertension, type 2 diabetes Introduction Patients with type 2 diabetes (T2D) and/or hypertension who fail to achieve therapeutic targets despite guideline‐directed therapy are frequently encountered in clinical practice [1, 2]. In these patients, glucose levels and blood pressure remain elevated despite treatment with multiple agents, driving a continuous rise in cardiometabolic risk. When conventional therapies fall short, clinicians must consider whether an unrecognized biologic factor is driving this resistance. Increasingly, data point to endogenous hypercortisolism in a significant subset of these patients [3, 4, 5]. For decades, hypercortisolism was largely synonymous with overt Cushing syndrome, characterized by moon facies, violaceous striae, proximal muscle weakness, easy bruising, osteoporosis, and hypokalemia [6, 7, 8, 9]. Such classic presentations, while still encountered, are no longer the only recognized form of cortisol excess. In routine clinical practice, the clinical picture often lacks classic Cushingoid features, typically presenting as metabolic disease that remains difficult to control despite appropriate therapy [10]. Relying only on overt Cushingoid features risks underrecognition, whereas indiscriminate testing increases the likelihood of equivocal results [3, 4, 5]. However, increased awareness and targeted screening in high‐risk populations have expanded recognition beyond patients with these classic features to include a broader group of individuals with clinically significant cortisol excess who lack overt physical stigmata and who historically may have remained undiagnosed [5, 7, 10, 11]. In routine clinical practice, many patients with hypercortisolism present without classic Cushingoid features; instead, their primary clinical expression of cortisol excess is difficult‐to‐control diabetes, resistant hypertension, or other cardiometabolic complications that carry substantial morbidity and mortality [10, 12, 13, 14, 15]. This review addresses three practical questions: which patients warrant testing, how to interpret the results, and when treatment should be initiated. Cortisol raises hepatic glucose output, impairs insulin sensitivity, promotes visceral fat accumulation, increases vascular tone, and activates mineralocorticoid receptors—mechanisms that sustain hyperglycemia and hypertension [16, 17, 18, 19, 20]. These same pathways underlie many treatment‐resistant forms of diabetes and hypertension [10, 21]. Mild autonomous cortisol secretion (MACS)—defined in the context of adrenal incidentaloma guidelines as ACTH‐independent cortisol secretion identified by a post‐dexamethasone serum cortisol > 50 nmol/L (> 1.8 μg/dL) in the presence of an adrenal adenoma and in the absence of overt signs or symptoms of Cushing syndrome [4, 22]—is diagnosed in 20%–50% of patients with adrenal incidentalomas [22, 23]. Because adrenal incidentalomas are detected in up to 5% of adults undergoing cross‐sectional imaging [23, 24], MACS represents a substantial and under‐recognized burden of cortisol excess in the broader population. Despite the descriptor “mild,” which refers to the degree of biochemical cortisol non‐suppressibility and the absence of classic Cushingoid features rather than to clinical consequences, MACS is associated with clinically significant increases in hypertension (RR 1.24), T2D (RR 1.44), dyslipidemia (RR 1.23), and all‐cause mortality (HR 1.54) [25]. Confirmed endogenous hypercortisolism is generally found in 0.6%–3.4% of broader T2D cohorts after stepwise biochemical evaluation [7, 8, 12, 26], although some studies using less stringent confirmation criteria have reported rates as high as approximately 9% [7]. A recent large meta‐analysis reported that among 6638 patients with diabetes screened across 22 studies, 14.3% had an abnormal dexamethasone suppression test (DST), but only 2.1% had confirmed Cushing syndrome; among 8705 patients with obesity screened across 19 studies, the corresponding rates were 4.6% and 0.8%, respectively—underscoring the gap between screening positivity and confirmed disease [26]. Recent prospective prevalence studies suggest that abnormal cortisol suppression is substantially more common in selected high‐risk groups than in unselected diabetes populations. In the CATALYST study, 23.8% of 1057 patients with difficult‐to‐control T2D had a positive overnight DST with protocolized dexamethasone level confirmation [11]. A similar signal has been reported in resistant hypertension. In MOMENTUM, 27.3% of 1086 patients with American Heart Association‐defined resistant hypertension had cortisol non‐suppression on screening DST, with rates above 30% in those with elevated HbA1c or treatment with three or more antihypertensive drugs; however, these findings are currently derived from a design paper and conference‐level primary results rather than a full peer‐reviewed outcomes publication [13, 14]. These figures represent biochemically confirmed cortisol non‐suppression in enriched populations rather than population‐level disease prevalence, but they support the view that cortisol dysregulation is a potentially modifiable contributor to cardiometabolic risk that is substantially underrecognized in routine practice. When hypercortisolism is identified, effective treatment options exist. Surgery can be curative when a discrete pituitary or adrenal lesion is present, and medical therapies—including glucocorticoid‐receptor antagonists and steroidogenesis inhibitors—offer effective alternatives when surgery is not feasible, not curative, or not aligned with patient preference. These treatment options, their evidence base, and practical considerations for their use are discussed in detail later in this review. Biology and Clinical Rationale Cortisol helps maintain vascular tone, regulate glucose, support immune responses, and manage stress [6, 16]. Continuous, moderate cortisol elevation produces metabolic and vascular effects commonly encountered in clinical practice [5, 6, 10]. Hypercortisolism is best understood as a continuum of risk, from mild autonomous cortisol secretion (MACS) to overt Cushing syndrome, with cardiometabolic complications increasing as cortisol becomes more independent of normal feedback [5, 6, 7, 9, 10, 15, 22, 27]. The older term “subclinical Cushing syndrome” implied a silent condition waiting to declare itself. Current guidelines prefer MACS, recognizing that many patients still have some ACTH regulation but show clear biochemical and metabolic effects [3, 4, 5, 22]. This framework treats cortisol excess as a graded risk factor rather than a binary diagnosis. Pathophysiology The liver responds to cortisol by increasing gluconeogenic enzymes and reducing hepatic insulin sensitivity [28, 29]. In skeletal muscle, cortisol impairs GLUT‐4 translocation and insulin signalling, which lowers glucose uptake [29, 30]. The net effect—increased hepatic glucose output and reduced peripheral uptake—produces the hyperglycemia characteristic of treatment‐resistant diabetes [8]. Cortisol also negatively affects beta cell function, leading to greater fasting and postprandial hyperglycemia [31]. On the vascular side, cortisol increases vascular resistance by boosting catecholamine reactivity, promoting endothelin‐1, and limiting nitric oxide availability [17, 18, 32]. It also promotes sodium retention through mineralocorticoid‐receptor activation and by overwhelming 11β‐hydroxysteroid dehydrogenase type 2 [19, 20]. Even cortisol concentrations below classic Cushing thresholds are associated with higher systolic blood pressure and increased left‐ventricular mass [15]. Systemic Effects Chronic cortisol excess favours storage of fat in the abdominal region and drives muscle tissue catabolism, leading to visceral obesity, sarcopenia, and functional decline [33, 34]. It inhibits osteoblast activity and stimulates osteoclasts, reducing bone mineral density and raising fracture risk [35]. Metabolic decline is often accompanied by insomnia and depression; sleep becomes fragmented, mood worsens, and cognition can be dulled [36]. These symptoms frequently appear alongside worsening metabolic control and can serve as indirect clinical clues that cortisol is contributing. Population Impact As discussed in the Introduction, confirmed endogenous hypercortisolism is found in 0.6%–3.4% of broader T2D cohorts after stepwise biochemical evaluation [8, 12, 26], and MACS—despite the “mild” descriptor—is associated with clinically substantial increases in hypertension, diabetes, dyslipidemia, and all‐cause mortality [25]. Recent prospective studies in enriched populations (CATALYST, MOMENTUM) have reported abnormal cortisol suppression in roughly one in four patients with difficult‐to‐control T2D or resistant hypertension [13, 37, 38]. This section examines what these figures mean in clinical context. These DST screening‐positive rates must be interpreted carefully. A positive DST identifies patients who warrant further endocrine evaluation, not patients in whom hypercortisolism has already been established [39, 40]. It is also important to distinguish between isolated cortisol non‐suppression and MACS, which in current adrenal incidentaloma guidelines requires both biochemical evidence of autonomy and an adrenal lesion [4, 39, 41]. In CATALYST, only 34.7% of patients with screening‐positive results had adrenal imaging abnormalities, underscoring that many patients with abnormal screening tests do not meet formal MACS criteria [37]. In overt Cushing syndrome, cardiovascular mortality is estimated to be approximately two‐ to five‐fold higher than in the general population, whereas in MACS the excess risk appears smaller and more heterogeneous [9, 10, 38]. Emerging data suggest a graded relationship between higher post‐DST cortisol values and increased mortality, with risk significantly elevated at cortisol levels ≥ 83 nmol/L [42]. Even so, the high frequency of DST non‐suppression in difficult‐to‐control T2D and resistant hypertension suggests that cortisol dysregulation may contribute to cardiometabolic risk in selected patients who would otherwise be managed only with escalating polypharmacy [10, 13, 37, 38]. For this reason, targeted case‐finding in patients with multiple, progressive, or atypical features may uncover an endocrine contributor to otherwise unexplained metabolic resistance. However, positive screening results should be followed by appropriate confirmatory testing and specialist assessment rather than being treated as a diagnosis in themselves [7, 39, 40]. Recognizing High‐Yield Phenotypes In day‐to‐day practice, hypercortisolism usually presents through familiar metabolic problems that do not improve with standard therapy. The objective is focused suspicion rather than broad screening (Table 1) [5]. TABLE 1When to suspect hypercortisolism: high‐yield clinical phenotypes.Clinical phenotypeKey features prompting testingScreening positivity (DST)ReferencesDifficult‐to‐control T2DHbA1c 7.5%–11.5% on ≥ 3 agents, or ≥ 2 agents+insulin or complications; persistent fasting hyperglycemia despite overnight insulin23.8% (CATALYST); 33.3% with cardiac comorbidities[11, 27, 36]Resistant hypertensionBP above goal on ≥ 3 drugs (incl. diuretic) or controlled only on ≥ 427.3% (MOMENTUM); > 30% if on ≥ 3 agents or elevated HbA1c[13, 14, 38, 43]Both conditions resistantConcurrent treatment‐resistant T2D + HTN in the same patientHighest yield; 36.6% on ≥ 3 BP meds (CATALYST)[3, 4, 5, 11, 37]Adrenal incidentalomaAny incidental adrenal mass, especially with worsening metabolic comorbidities20%–30% secrete cortisol autonomously[4, 5, 11, 22]Unexplained catabolic signsEasy bruising, proximal weakness, thin skin, slow wound healing, low‐trauma fractures—without exogenous steroidsClinical suspicion; no population‐level screening rate[33, 34, 35] Note: Routine screening of all patients with T2D or hypertension is NOT recommended. Test only when multiple, progressive, or atypical features are present.Abbreviations: BP, blood pressure; DST, overnight 1‐mg dexamethasone suppression test; HTN, hypertension; T2D, type 2 diabetes. When to suspect hypercortisolism: high‐yield clinical phenotypes. Note: Routine screening of all patients with T2D or hypertension is NOT recommended. Test only when multiple, progressive, or atypical features are present. Abbreviations: BP, blood pressure; DST, overnight 1‐mg dexamethasone suppression test; HTN, hypertension; T2D, type 2 diabetes. Difficult‐to‐Control T2D Concern arises when glycemic control remains inadequate despite intensive multidrug therapy. In the CATALYST study, this was operationalized as HbA1c 7.5%–11.5% despite treatment meeting at least one of: taking three or more glucose‐lowering agents, taking insulin with any other glucose‐lowering medication, taking two or more glucose‐lowering medications with microvascular or macrovascular complications, or taking two or more glucose‐lowering and two or more blood pressure–lowering medications [11]. Among 1057 patients meeting these criteria, 23.8% had cortisol non‐suppression on screening DST, rising to 33.3% in those with cardiac comorbidities [11]. This difficult glycemic control is often accompanied by persistent morning hyperglycemia despite overnight insulin, truncal weight gain, proximal muscle weakness, fatigue, and disturbances of sleep or mood [27, 36]. Recognizing this pattern can shift management from simply adding more antihyperglycemic medications to the targeted treatment of hypercortisolism. Resistant Hypertension Resistant hypertension affects about 10%–15% of treated patients who require at least three medications or reach blood‐pressure targets only with four or more [43, 44]. Historically, about 10%–15% of these patients showed impaired cortisol suppression on testing [5, 18, 43]. However, recent data from MOMENTUM indicate a 27.3% rate of cortisol non‐suppression in resistant hypertension, exceeding 30% in patients taking three or more medications or with elevated HbA1c; these data should be interpreted cautiously pending full peer‐reviewed publication of the primary results [13, 14]. Similarly, in CATALYST, 36.6% of patients taking three or more blood‐pressure medications had abnormal cortisol suppression on screening DST [11]. After excluding primary aldosteronism, renal disease, and obstructive sleep apnea, clinicians should consider cortisol testing because cortisol‐mediated changes in vascular reactivity and sodium retention identify a patient group with a higher likelihood of a positive result [19, 20]. Clinical clues include sensitivity to volume changes with fluctuating edema, mild hypokalemia frequently attributed to diuretics, and fatigue disproportionate to the degree of blood pressure control [19, 20]. When Both Conditions Resist Treatment Diagnostic yield is greatest when both T2D and hypertension fail to respond to standard therapy in the same patient. A single 1‐mg DST may reveal one underlying endocrine cause behind what otherwise appears to be two separate resistant conditions [3, 4, 5, 43]. Adrenal Incidentaloma With Metabolic Disease Estimates of autonomous cortisol secretion among adrenal incidentalomas range widely—from approximately 10%–50% depending on diagnostic criteria and study population—with most guideline‐cited estimates in the range of 20%–30% [4, 5, 22]. In the CATALYST cohort, 34.7% of patients with hypercortisolism had adrenal imaging abnormalities, predominantly unilateral nodules [11]. Even mild hormonal activity can worsen cardiometabolic risk and reduce bone mineral density. Endocrine evaluation should include the 1‐mg overnight DST as the recommended first‐line biochemical assessment for autonomous cortisol secretion, along with imaging correlation [4, 5, 45]. Adenoma size alone does not predict hormonal activity; adenomas smaller than 2 cm can be biochemically active, while some larger nodules remain silent [45]. If glycemia or blood pressure worsened after an incidentaloma was discovered, repeat biochemical testing is indicated [5]. When initial biochemical evaluation is normal, the 2023 ESE‐ENSAT guideline recommends against routine repeated hormonal work‐up, unless new clinical signs of endocrine activity appear or comorbidities such as hypertension or T2D develop or worsen. This recommendation was strengthened in the 2023 guideline compared with the 2016 edition, reflecting accumulating evidence that the risk of developing clinically significant new hormone excess is very low [4, 5]. Catabolic Signs Clinicians should also look for unexplained bruising, proximal weakness, thin skin, slow wound healing, or low‐trauma fractures in patients not taking exogenous steroids. These findings strongly suggest cortisol excess but are often dismissed as aging or medication effects [33, 34, 35]. Ultimately, most patients do not fit a single phenotype. The overall pattern of overlapping abnormalities, rather than any one feature, provides the clearest diagnostic clues [5, 6, 7, 46]. Diagnostic Approach and the 1‐mg DST Once clinical suspicion is established, diagnostic testing must be targeted. For evaluation of mild autonomous cortisol secretion in adrenal incidentaloma and for pragmatic case‐finding in selected high‐risk phenotypes, the overnight 1‐mg DST is often the most practical first‐line tool because it is simple, inexpensive, and well validated (Table 2) [3, 4, 11, 25, 43, 52]. The 2023 ESE‐ENSAT guideline identifies the 1‐mg DST as the most sensitive first‐line test for detecting autonomous cortisol secretion (R.3.2), and its diagnostic value is greatest when results are interpreted in the context of the patient's overall clinical picture and comorbidity burden rather than as an isolated biochemical finding [4]. By contrast, in suspected overt Cushing syndrome, major guidelines consider the DST, late‐night salivary cortisol, and 24‐h urinary free cortisol to be acceptable first‐line tests, and diagnosis generally requires more than one abnormal result under appropriate clinical conditions [3, 53]. TABLE 2Overnight 1‐mg DST: Interpretation and common pitfalls.Panel A: Result interpretationPost‐DST serum cortisolInterpretationNext stepsReferences≤ 50 nmol/L (≤ 1.8 μg/dL)Normal suppression—autonomous cortisol secretion excludedNo further endocrine workup required for hypercortisolism. If clinical suspicion remains high (e.g., classic Cushingoid features), consider late‐night salivary cortisol or 24‐h UFC and endocrine referral.[3, 4]> 50 nmol/L (> 1.8 μg/dL)Mild autonomous cortisol secretion (MACS)—a single diagnostic threshold without further stratification by degree of non‐suppressibility (ESE‐ENSAT 2023, R.3.4)Confirm test validity (see Panel C). Evaluate for pseudo‐Cushing states. Repeat 1‐mg DST and obtain morning ACTH to confirm autonomous cortisol secretion. Late‐night salivary cortisol and 24‐h UFC can help assess the degree of hypercortisolism but have a high false‐negative rate for MACS and should not be used to exclude it. Defer imaging until biochemical confirmation is secured. Refer to endocrinology for further evaluation.[3, 4, 42]Panel B: Common causes of misleading resultsCategoryCauseMechanismEffect on DSTReferencesPharmacologicCYP3A4 inducers (phenytoin, carbamazepine, rifampin, barbiturates)Accelerate dexamethasone metabolism → inadequate suppressionFalse positive[3, 47]PharmacologicCYP3A4 inhibitors (ketoconazole, ritonavir)Slow dexamethasone metabolism → excessive suppressionFalse negative[47]PharmacologicOestrogen therapy (oral contraceptives, HRT)Increases CBG → raises total cortisol while free cortisol unchangedFalse positive[48]Physiologic/behaviouralHeavy alcohol useHPA axis activationFalse positive[3, 49, 50]Physiologic/behaviouralMajor depressionHPA axis activationFalse positive[3, 49, 50]Physiologic/behaviouralUntreated obstructive sleep apneaHPA axis activationFalse positive[3, 49, 50]Physiologic/behaviouralAcute illness or physiologic stressHPA axis activationFalse positive[3]Test‐relatedPoor timing, non‐adherence, malabsorptionInadequate dexamethasone exposureFalse positive[3, 47]Panel C: Confirming test validityStepRationaleReferencesMeasure serum dexamethasone level alongside morning cortisolConfirms the patient took the pill and absorbed it adequately. Inadequate dexamethasone levels, whether due to non‐adherence, malabsorption, or accelerated CYP3A4‐mediated metabolism, are a recognized cause of false‐positive results. This simple step can spare patients from unnecessary additional testing.[4, 46]Minimum dexamethasone thresholdThe CATALYST protocol required a serum dexamethasone level ≥ 140 ng/dL to validate the test. If levels were low, testing was repeated with a higher dose to ensure adequate suppression.[11, 37]Exclude pseudo‐Cushing states before proceedingHeavy alcohol use, major depression, severe untreated OSA, and oestrogen‐containing contraceptives should be addressed or discontinued before testing or retesting.[3, 11, 37, 49, 50]Panel D: Clinical integration factorsFactorRelevanceReferencesComorbidity burdenThe number and severity of comorbidities potentially attributable to cortisol excess (T2D, hypertension, osteoporosis, dyslipidemia) should weigh more heavily in clinical decision‐making than the absolute post‐DST cortisol value.[4, 9, 22, 23]Age and sexMortality risk associated with MACS varies by age and sex; younger women with MACS show the greatest relative excess mortality.[10]ACTH statusMorning ACTH helps distinguish ACTH‐independent (adrenal) from ACTH‐dependent (pituitary/ectopic) sources and guides subsequent imaging and management.[3, 4, 40]Adrenal imaging findingsImaging should be obtained only after biochemical confirmation. Adenoma size alone does not predict hormonal activity.[4, 39, 45]Temporal trajectoryWorsening metabolic control over time in the setting of confirmed cortisol non‐suppression strengthens the case for intervention.[5, 10, 51] Note: A positive DST warrants further evaluation—it does not establish a diagnosis. Imaging should be deferred until biochemical confirmation is obtained [4, 42]. Post‐DST cortisol should be interpreted as a continuous variable reflecting graded cardiometabolic risk, not as a binary result. Higher values are associated with greater morbidity and mortality, but the presence and severity of comorbidities potentially attributable to cortisol excess—not the absolute cortisol value alone—should guide clinical decision‐making [4, 9, 22, 42].Abbreviations: ACTH, adrenocorticotropic hormone; CBG, cortisol‐binding globulin; DST, dexamethasone suppression test; HPA, hypothalamic–pituitary–adrenal; HRT, hormone replacement therapy; MACS, mild autonomous cortisol secretion; OSA, obstructive sleep apnea; T2D, type 2 diabetes; UFC, urinary free cortisol. Overnight 1‐mg DST: Interpretation and common pitfalls. Note: A positive DST warrants further evaluation—it does not establish a diagnosis. Imaging should be deferred until biochemical confirmation is obtained [4, 42]. Post‐DST cortisol should be interpreted as a continuous variable reflecting graded cardiometabolic risk, not as a binary result. Higher values are associated with greater morbidity and mortality, but the presence and severity of comorbidities potentially attributable to cortisol excess—not the absolute cortisol value alone—should guide clinical decision‐making [4, 9, 22, 42]. Abbreviations: ACTH, adrenocorticotropic hormone; CBG, cortisol‐binding globulin; DST, dexamethasone suppression test; HPA, hypothalamic–pituitary–adrenal; HRT, hormone replacement therapy; MACS, mild autonomous cortisol secretion; OSA, obstructive sleep apnea; T2D, type 2 diabetes; UFC, urinary free cortisol. Physiologic Basis Dexamethasone is a potent synthetic glucocorticoid with high glucocorticoid receptor affinity and negligible mineralocorticoid activity. In healthy individuals, 1 mg suppresses corticotropin‐releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secretion sufficiently to produce near‐complete adrenal suppression by morning [40]. The test effectively assesses hypothalamic–pituitary–adrenal feedback and can reveal inappropriate cortisol autonomy. Clinical and Pharmacologic Context Interpretation heavily depends on the clinical and pharmacologic context. False‐positive results (failure to suppress) can occur due to poor test timing, non‐adherence, malabsorption, or concurrent use of drugs that accelerate hepatic CYP3A4‐mediated dexamethasone clearance, such as phenytoin, carbamazepine, rifampin, and barbiturates [3, 47]. Conversely, CYP3A4 inhibitors such as ketoconazole or ritonavir can inappropriately increase suppression [47]. Furthermore, oestrogen therapy raises cortisol‐binding globulin, increasing total serum cortisol while free cortisol remains unchanged, which can also confound results [48]. A simple but underutilized step to improve diagnostic accuracy is concurrent measurement of serum dexamethasone levels alongside morning cortisol. This confirms that the patient took the pill and absorbed it adequately, preventing unnecessary further workup triggered by what is essentially a failed test rather than true cortisol non‐suppression. Inadequate dexamethasone levels—whether due to non‐adherence, malabsorption, or accelerated CYP3A4‐mediated metabolism—are a recognized cause of false‐positive results. The 2023 ESE‐ENSAT guideline acknowledges that measurement of serum dexamethasone alongside cortisol may help exclude false‐positive DST results, though this method is not yet widely available [4]. The CATALYST investigators applied this principle by setting a minimum serum dexamethasone level of 140 ng/dL to validate the test. The study protocol specified that if initial dexamethasone levels were inadequate, testing could be repeated with a higher dose to ensure adequate suppression [11, 37]. This supplementary step helps reduce false‐negative interpretations stemming from poor absorption or non‐adherence. Pseudo‐Cushing States Pseudo‐Cushing states—also termed physiologic or non‐neoplastic hypercortisolism—are conditions that produce genuine hypothalamic–pituitary–adrenal (HPA) axis activation sufficient to cause partial cortisol non‐suppression on DST, even though autonomous cortisol secretion is not present. Although the term remains widely used in endocrinology, it is increasingly recognized as an imprecise clinical construct that encompasses a heterogeneous group of conditions rather than a single disease entity and lacks a universally accepted diagnostic definition. Common causes include major depression, heavy alcohol use, chronic illness, and untreated obstructive sleep apnea (OSA). The key clinical distinction is that cortisol abnormalities in these states typically resolve when the underlying condition is treated, whereas pathologic hypercortisolism persists [3, 49]. When a pseudo‐Cushing state is suspected, clinicians should stabilize the underlying condition and repeat testing rather than proceeding directly to hypercortisolism treatment [3, 49, 50]. The CATALYST protocol addressed this by excluding patients with heavy alcohol use, severe untreated OSA, and those taking oestrogen‐containing contraceptives prior to testing [11, 37]. Post‐DST Cortisol Above the Diagnostic Threshold The 2023 ESE‐ENSAT guideline recommends a single diagnostic threshold: post‐DST serum cortisol > 50 nmol/L (> 1.8 μg/dL) indicates mild autonomous cortisol secretion (MACS) without further stratification based on the degree of non‐suppressibility [4]. When post‐DST cortisol exceeds this threshold, further evaluation is warranted. In suspected overt Cushing syndrome, this includes late‐night salivary cortisol, 24‐h urinary free cortisol, and morning ACTH measurements [3, 9, 53]. In the MACS setting, the ESE‐ENSAT guideline recommends repeating the 1‐mg DST and measuring morning ACTH to confirm autonomous cortisol secretion; while late‐night salivary cortisol and 24‐h urinary free cortisol can help assess the degree of hypercortisolism, these tests have a high false‐negative rate for MACS and should not be used to exclude it [4, 23]. The presence and severity of comorbidities potentially attributable to cortisol excess—rather than the absolute post‐DST cortisol value—should guide clinical decision‐making, as emerging data suggest a graded relationship between higher post‐DST cortisol values and increased morbidity and mortality [4, 10, 42]. Imaging to localize the source of cortisol excess should be deferred until after biochemical confirmation; premature imaging risks misattributing the cause to a non‐functioning incidentaloma [4, 42]. Clinical Integration Diagnostic confidence is highest when biochemical evidence and the clinical phenotype point in the same direction [5, 6, 7, 43]. The 1‐mg DST is a targeted case‐finding tool, not a universal screening test for all patients with diabetes or hypertension. Patients with treatment‐resistant metabolic disease who demonstrate cortisol non‐suppression above the diagnostic threshold, particularly in the presence of comorbidities consistent with cortisol excess, are the most appropriate candidates for further evaluation and therapeutic intervention [3, 4, 5]. Routine screening of all patients with diabetes or hypertension is not recommended. Rather, testing should be reserved for patients with multiple, progressive, or atypical features suggestive of cortisol excess (such as concurrent treatment‐resistant diabetes and hypertension, unexplained osteoporosis, or proximal myopathy), or for those with adrenal incidentalomas in whom autonomous cortisol secretion is a realistic diagnostic possibility [3, 4, 7, 46]. When to Treat Hypercortisolism It is important to consider addressing the underlying cortisol excess to reduce its adverse cardiometabolic consequences. Treatment decisions should be individualized based on each patient's clinical presentation. When biochemical evidence and clinical context align, intervention should not be unduly delayed, as accumulating data demonstrate that untreated hypercortisolism—even at the MACS end of the spectrum—is associated with increased cardiometabolic morbidity and mortality [10, 25, 44, 51]. The decision to treat relies on the alignment of three core elements: biochemical confidence, phenotypic severity, and clear therapeutic goals [3, 4, 5, 36, 43]. An abnormal biochemical result is clinically actionable when excess cortisol is contributing to the patient's cardiometabolic burden and when intervention is likely to improve outcomes. Biochemical Confidence Test results must be reproducible and obtained under optimal conditions. A single abnormal DST during an acute illness or while the patient is taking an interacting medication is insufficient to justify treatment [3, 47]. However, once confounders have been excluded and cortisol non‐suppression is confirmed, the emphasis should shift from repeated retesting to clinical integration and specialist evaluation, as excessive reassessment may delay appropriate intervention [4]. Phenotypic Assessment Clinicians must evaluate both the current severity of the disease and how the clinical picture has evolved over time. As detailed earlier, MACS is associated with clinically significant increases in hypertension, T2D, and all‐cause mortality [25], and conservative management without addressing cortisol excess is associated with adverse cardiovascular outcomes over time [51, 54]. Recent RCT evidence from CHIRACIC and Morelli et al. demonstrates that adrenalectomy improves blood pressure and metabolic control in patients with MACS and unilateral adrenal adenomas [55, 56]. At the same time, the ESE‐ENSAT 2023 guideline recommends an individualized approach, and the largest observational study (Deutschbein et al. 2022, n = 3656) concluded that conservative management remains justified in most patients pending further RCT data on hard cardiovascular endpoints [10]. Accordingly, progressive metabolic worsening—particularly when accompanied by comorbidities plausibly attributable to cortisol excess—should prompt consideration of targeted intervention rather than continued escalation of conventional therapy [4, 5, 43]. Goal Definition Therapeutic objectives should be explicitly defined—such as achieving improved glycemic control, lowering blood pressure, or reducing the daily medication burden—and aligned with what the patient prioritizes [53]. Overt or rapidly progressive Cushing syndrome—characterized by marked hyperglycemia, uncontrolled hypertension, hypokalemia, recurrent infections, or muscle wasting—requires prompt endocrine evaluation and immediate treatment [3, 6, 16]. For patients with difficult‐to‐control diabetes or resistant hypertension and confirmed cortisol autonomy, targeted treatment is warranted once cortisol's pathophysiologic contribution is established. Supporting this approach, the treatment phase of CATALYST demonstrated that patients with T2D and screening‐detected hypercortisolism randomized to mifepristone achieved an HbA1c reduction 1.32 percentage points greater than placebo (95% CI −1.81 to −0.83; p < 0.001), along with significant reductions in body weight (−5.1 kg) and waist circumference (−5.1 cm) [57]. These metabolic benefits emerged by 12 weeks and persisted through 24 weeks. Notably, treatment effects were comparable between patients with and without adrenal imaging abnormalities, suggesting that cortisol‐directed therapy may benefit a broader population of patients with hypercortisolism‐associated T2D than those meeting traditional MACS criteria defined by the presence of an adrenal lesion [57]. However, these benefits must be weighed against a substantial discontinuation rate and anticipated class‐effect adverse events, discussed in detail in the Treatment Options section [57]. Accordingly, decisions to use mifepristone in this setting should be individualized, based on repeat biochemical evaluation and clear clinical relevance, and made in conjunction with an endocrinologist [40]. When test results are potentially confounded—such as in the setting of heavy alcohol use, major depression, or acute illness—reversible factors should be addressed and testing repeated before committing to therapy [49, 50]. Additionally, in frail patients with a limited life expectancy, comfort‐focused care may be the most appropriate path [40]. The clinical trajectory is the primary guide: a worsening cardiometabolic profile supports intervention, whereas stability without attributable comorbidities may justify continued observation with regular reassessment [4, 5, 10]. Treatment Options Management depends on aetiology, severity, and comorbidities (Table 3). The primary therapeutic approach involves removing an evident source of excess cortisol whenever possible; otherwise, the focus shifts to reducing cortisol activity at the receptor level or reducing cortisol production [3, 4, 5, 40]. TABLE 3Treatment options for confirmed hypercortisolism.ModalityAgent/approachKey efficacy dataImportant safety considerationsReferencesSurgery—adrenalLaparoscopic adrenalectomyApproaching 100% remission (adrenal adenoma); CHIRACIC: 46% BP normalization versus 15% conservative (MACS)Adrenal insufficiency in ~50%; recovery up to 6.5 months; requires perioperative stress‐dose glucocorticoids[40, 55, 58, 59, 60, 61]Surgery—pituitaryTranssphenoidal resection70%–80% cure rate; up to ~90% at high‐volume centersAdrenal insufficiency risk; expertise‐dependent outcomes[40, 58, 60]GR antagonistMifepristone (FDA‐approved for hyperglycemia in Cushing syndrome)SEISMIC: 60% glycemic/38% BP improvement; CATALYST: HbA1c—1.32% versus placebo, −5.1 kg weightBoxed warning: terminates pregnancy. Hypokalemia (44%), endometrial thickening (38% of women), nausea, fatigue; 46% all‐cause discontinuation (includes non‐AE reasons). Cortisol levels do NOT reflect efficacy[57, 62, 63, 64, 65]Selective GR modulatorRelacorilant (GRACE trial; investigational for hypercortisolism)5.9× more likely to maintain HTN response versus placebo in Cushing syndrome; fewer mineralocorticoid‐related AEs; no drug‐induced hypokalemia or QT prolongationNo anti‐progesterone activity; FDA‐approved for platinum‐resistant ovarian cancer; data not yet applicable to screening‐positive populations[66, 67]Steroidogenesis inhibitorOsilodrostat (FDA‐approved)LINC‐3: 53% UFC normalization at wk. 24; 86% versus 29% placebo (withdrawal phase). LINC‐4: 77% versus 8% placeboAdrenal insufficiency (~50%, dose‐adjustable); QT prolongation[68, 69, 70, 71]Steroidogenesis inhibitorLevoketoconazole (FDA‐approved)SONICS: 31% UFC normalizationBoxed warning: Hepatotoxicity risk; QT prolongation; monitor LFTs[65, 72]Steroidogenesis inhibitorMetyrapone (off‐label in US)~45%–55% efficacy (UFC normalization/cortisol day‐curve control); rapid onsetHirsutism, hypokalemia, nausea; monitor cortisol levels closely[73, 74, 75]Pituitary‐directedPasireotide LAR (FDA‐approved for Cushing disease)~40% cortisol normalizationHyperglycemia (may worsen diabetes)[76]Pituitary‐directedCabergoline~30%–40% initial response; ~20%–25% sustained (treatment escape)Generally well tolerated; treatment escape limits sustained response[53, 73] Note: All medical therapies require endocrinologist supervision. As cortisol activity declines, anticipate need to reduce insulin and antihypertensive doses to prevent hypoglycemia and hypotension. Monitor electrolytes, hepatic function, and ECG (QTc) as appropriate to each agent.Abbreviations: AEs, adverse events; BP, blood pressure; GR, glucocorticoid receptor; HTN, hypertension; LFTs, liver function tests; MACS, mild autonomous cortisol secretion; QTc, corrected QT interval; UFC, urinary free cortisol. Treatment options for confirmed hypercortisolism. Note: All medical therapies require endocrinologist supervision. As cortisol activity declines, anticipate need to reduce insulin and antihypertensive doses to prevent hypoglycemia and hypotension. Monitor electrolytes, hepatic function, and ECG (QTc) as appropriate to each agent. Abbreviations: AEs, adverse events; BP, blood pressure; GR, glucocorticoid receptor; HTN, hypertension; LFTs, liver function tests; MACS, mild autonomous cortisol secretion; QTc, corrected QT interval; UFC, urinary free cortisol. Surgery Surgical resection provides the best chance of durable remission when a clearly identifiable lesion is present and aetiology and laterality permit. For overt Cushing syndrome, biochemical remission rates approach 100% after laparoscopic adrenalectomy for unilateral cortisol‐secreting adrenal adenomas, and approximately 70%–80% of patients with pituitary microadenomas achieve remission after transsphenoidal resection, with rates up to 90% reported from high‐volume centers [40, 58, 59]. Metabolic improvements typically begin within months, though the timeline varies: blood pressure often improves within weeks, glycemia within 3–12 months, and bone density over years [40, 52, 60]. For patients with MACS and a unilateral adrenal adenoma, adrenalectomy should be discussed when cortisol‐related comorbidities are present, particularly hypertension, hyperglycemia, or vertebral fractures [4, 23]. The CHIRACIC trial—the first multicenter RCT evaluating adrenalectomy for MACS with hypertension—demonstrated that 46% of patients randomized to surgery achieved blood pressure normalization with reduced antihypertensive treatment, compared with 15% in the conservative management group (adjusted risk difference 0.34; 95% CI 0.11–0.58; p = 0.0038). Notably, 12 (52%) of 23 surgical completers were off all antihypertensive medications at study completion, compared with none in the conservative group [55]. A systematic review and meta‐analysis similarly found that adrenalectomy for MACS improved hypertension in 61% and diabetes in 52% of patients, with significantly greater improvement compared with conservative management [77]. However, guideline recommendations on surgical indications for MACS vary: the American Association of Endocrine Surgeons gives a strong recommendation for adrenalectomy in MACS with a unilateral adenoma [78], whereas the ESE‐ENSAT guidelines recommend individualized discussion based on patient characteristics, comorbidity burden, and surgical risk [4]. An important practical consideration is that adrenal insufficiency develops postoperatively in approximately 50% of MACS patients and may take up to 6.5 months to resolve [23, 40, 61]. Clinicians must provide stress‐dose glucocorticoids perioperatively and implement a careful tapering regimen, with ongoing monitoring for signs of adrenal crisis [40, 79]. Glucocorticoid‐Receptor Antagonism When hyperglycemia is the dominant clinical problem and surgery is not feasible, not curative, or declined by the patient, glucocorticoid‐receptor antagonism can improve metabolic control. Mifepristone is a competitive glucocorticoid receptor antagonist that competes with cortisol for receptor binding. In the SEISMIC trial, mifepristone improved glycemia in 60% and blood pressure in 38% of patients with overt Cushing syndrome [62]. In the CATALYST treatment phase, mifepristone reduced HbA1c, body weight, BMI, and waist circumference in patients with difficult‐to‐control T2D and biochemical evidence of cortisol excess identified by screening [57]. These benefits, however, must be weighed against treatment burden and tolerability. In the published trial, 46% of participants receiving mifepristone discontinued therapy (compared with 18% on placebo); this all‐cause discontinuation rate includes participant withdrawal, loss to follow‐up, sponsor‐related decisions, and other non‐safety‐related factors—not adverse events alone. Adverse events occurring in more than 10% of mifepristone‐treated participants included hypokalemia, fatigue, nausea, vomiting, headache, peripheral edema, diarrhoea, and dizziness, along with increases in blood pressure; hypokalemia and symptoms consistent with cortisol withdrawal are anticipated class effects of glucocorticoid receptor antagonists, consistent with the known mechanism of action [57]. In the SEISMIC trial, hypokalemia was observed in 44% of patients during treatment [63]. Because mifepristone competes with cortisol at the glucocorticoid receptor without lowering circulating cortisol, treatment efficacy cannot be assessed biochemically and must instead be judged by clinical response and adverse‐effect monitoring [64, 65]. In women, vaginal bleeding and endometrial thickening are important adverse effects that should be discussed before treatment and monitored during therapy; in the SEISMIC trial, endometrial thickening above the upper limit of normal was reported in 38% of evaluable women [63]. Regulatory context and contraindications are essential for safe prescribing. Mifepristone is approved to control hyperglycemia secondary to endogenous Cushing syndrome in adults with T2D or glucose intolerance who have failed surgery or are not candidates for surgery; it is not approved for routine treatment of T2D in the absence of confirmed endogenous Cushing syndrome [63]. Therefore, use in patients with a positive screening DST but without confirmed Cushing syndrome is off‐label and should be undertaken only with endocrine supervision, careful review of drug interactions, and a clear discussion of expected benefits, uncertainties, and risks. Mifepristone carries a boxed warning for termination of pregnancy: pregnancy must be excluded before initiation and prevented during treatment using non‐hormonal contraception, as mifepristone's anti‐progesterone activity renders hormonal contraceptives ineffective [63]. Additional contraindications include concomitant use of simvastatin, lovastatin, or CYP3A substrates with narrow therapeutic ranges (cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus); use in patients receiving systemic corticosteroids for life‐saving purposes (e.g., post‐transplant immunosuppression); and use in women with unexplained vaginal bleeding or endometrial hyperplasia with atypia [63]. The drug also carries a warning for QT interval prolongation and should be avoided with QT‐prolonging medications or in patients at high risk for long QT‐related arrhythmia [63]. Because mifepristone is a strong CYP3A inhibitor, all concomitant medications should be carefully reviewed; CYP3A inducers (rifampin, phenytoin, carbamazepine, St. John's wort) should be avoided, and doses of CYP2C8/2C9 substrates should be reduced [63, 80]. Relacorilant, a selective glucocorticoid‐receptor modulator without anti‐progesterone activity, demonstrated a more favourable mineralocorticoid‐related adverse‐effect profile in the GRACE trial, a phase 3 randomized‐withdrawal study in patients with Cushing syndrome; relacorilant‐treated patients were 5.9 times more likely to maintain hypertension response versus placebo, with no drug‐induced hypokalemia, vaginal bleeding, or QT prolongation observed [66]. However, those data should not be assumed to apply directly to the screening‐positive cardiometabolic population emphasized in this review. Steroidogenesis Inhibition Steroidogenesis inhibition serves as an effective alternative when surgery is not feasible, not curative, or not aligned with patient preference. Among available agents, osilodrostat is the most potent adrenal steroidogenesis inhibitor [73]. In the LINC‐3 trial, osilodrostat achieved a complete response (UFC normalization) in 53% of patients at week 24, with 86% maintaining response versus 29% on placebo during the randomized withdrawal phase [68]. In the placebo‐controlled LINC‐4 trial, 77% of osilodrostat‐treated patients achieved UFC normalization at week 12 versus 8% on placebo (OR 43.4; p < 0.0001), with response sustained in 81% at week 36 [69]. A pooled analysis of LINC‐3 and LINC‐4 further demonstrated cardiometabolic benefits: 49.1% of patients with elevated systolic blood pressure achieved normalization by week 72, and antihypertensive medications were reduced or discontinued in 26.8% [70]. Metyrapone normalizes urinary free cortisol in approximately 45% of patients and achieves cortisol day‐curve control in approximately 55%, with a rapid onset of action [74, 75], while levoketoconazole normalized UFC in 31% of patients in the SONICS trial [72]. Osilodrostat is FDA‐approved for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has not been curative [71]; levoketoconazole is FDA‐approved for endogenous Cushing syndrome [72]; ketoconazole and metyrapone are used off‐label in the United States [73]. Hypocortisolism‐related adverse events occurred in approximately half of osilodrostat‐treated patients in LINC‐3, generally manageable with dose adjustment or temporary glucocorticoid replacement [68]. Regular biochemical monitoring is necessary with all steroidogenesis inhibitors to prevent adrenal insufficiency, mitigate hepatotoxicity (particularly with ketoconazole), and assess for QT prolongation [65]. Pituitary‐Directed Therapy For Cushing disease, when surgery is not feasible, not curative, or not aligned with patient preference, pituitary‐directed pharmacotherapy can be considered. Pasireotide LAR (long‐acting release), which is FDA‐approved specifically for Cushing disease, targets the somatostatin receptor subtype 5 and normalizes cortisol in approximately 40% of patients, though it carries a substantial risk of hyperglycemia [76]. Cabergoline normalizes urinary free cortisol in approximately 30%–40% of patients initially, though sustained long‐term control is maintained in only about 20%–25% due to treatment escape; it is generally well tolerated [53, 73]. Integrated Cardiometabolic Management As cortisol activity declines during treatment, insulin and antihypertensive requirements frequently decrease. In the CATALYST trial, dose reductions or discontinuations of fast‐acting insulin, long‐acting insulin, and sulfonylureas occurred in 30%, 49%, and 22% of mifepristone‐treated participants within the first 12 weeks, compared with 11%, 13%, and 11% on placebo, respectively [57]. Medication dose adjustments should be implemented promptly to prevent hypoglycemia and hypotension [52]. Care teams must regularly monitor electrolytes, administer temporary stress‐dose glucocorticoids during periods of transient adrenal insufficiency, and emphasize lifestyle modifications and sleep quality, particularly in cases where cortisol excess is at the milder end of the spectrum [5, 43]. Whether surgical or medical, the goals are the same: better metabolic control, fewer daily medications, and improved quality of life [6, 52, 81, 82, 83]. Monitoring Response Assessing therapeutic response matters as much as starting treatment. What counts is sustained improvement in metabolic control, blood pressure, physical function, and quality of life—not cortisol levels alone [52, 81, 82, 83]. Follow‐up evaluations should begin with a structured baseline that includes glucose and blood pressure measurements, medication burden, and functional status. Recovery typically unfolds in stages: within weeks, receptor antagonism or steroidogenesis inhibition often improves glucose and potassium levels; within a few months, blood pressure and sleep parameters frequently stabilize; and after 6–12 months, muscle mass and bone strength begin to recover [52, 60, 82]. Clinicians should counsel patients that biochemical improvement often precedes full clinical recovery, and that physical and psychological symptoms may take months to resolve even after cortisol levels normalize [40, 73]. Cortisol withdrawal syndrome—characterized by fatigue, arthralgia, myalgia, nausea, and mood disturbance despite biochemically adequate cortisol replacement—occurs in approximately 40%–67% of patients following curative adrenalectomy for adrenal Cushing syndrome, and is also commonly reported after transsphenoidal surgery for Cushing disease, though precise rates vary by aetiology and surgical approach. It can also develop during effective medical therapy that rapidly lowers cortisol exposure and should be anticipated, recognized, and managed supportively to avoid premature treatment discontinuation or unnecessary glucocorticoid dose escalation [65, 79, 84]. While cortisol testing remains useful, the appropriate biochemical approach depends on the chosen treatment modality. For patients taking steroidogenesis inhibitors, morning serum cortisol and 24‐h urinary free cortisol should be measured to monitor for oversuppression [68, 72, 74]. During receptor antagonism, dosing must be adjusted based on clinical response and adverse‐effect monitoring, as cortisol levels remain elevated and do not reflect therapeutic efficacy [57, 64, 85]. Notably, cortisol levels also cannot be used to diagnose adrenal insufficiency during mifepristone therapy; if adrenal insufficiency is suspected, treatment requires high‐dose dexamethasone (2–4 mg) rather than standard hydrocortisone replacement [63, 65]. Following curative surgery, early‐morning cortisol is measured to confirm remission, and subsequent ACTH‐stimulation testing is used to document adrenal recovery [40, 79]. Adverse‐event surveillance should continue throughout therapy. With steroidogenesis inhibitors, fatigue, low blood pressure, and liver enzyme changes (particularly with ketoconazole, which carries a boxed warning for hepatotoxicity) should be monitored; with receptor antagonists, hypokalemia and edema require attention; after surgery, fluid and electrolyte shifts need ongoing surveillance [65]. Early recognition of problems helps prevent adrenal crises and supports continued treatment [53, 65]. Successful treatment improves HbA1c and blood pressure without adding medications, normalizes potassium, restores energy and mood, and reduces the overall pill burden [52, 53, 82, 83]. If laboratory values normalize but clinical symptoms persist, the management plan should be reassessed and alternative etiologies investigated. For patients on steroidogenesis inhibitors, a change in treatment should be considered if cortisol levels remain persistently elevated after 2–3 months on maximum tolerated doses [53]. For overall clinical recovery—including improvements in body composition, bone density, and quality of life—if measurable improvement is absent after 6–9 months, or if surgical intervention becomes a viable option, the treatment strategy should be reevaluated. Conversely, patients who achieve stable remission after adrenalectomy for a benign adrenal adenoma can usually transition to less frequent monitoring, whereas those treated for Cushing disease require lifelong surveillance, as recurrence rates range from 5% to 35% and may occur more than 10 years after initial remission [40, 53, 81, 82]. The outcomes patients care about most are practical: fewer pills, better sleep, and the strength to get through the day [82, 83]. Clinical Implementation Integrating cortisol assessment into cardiometabolic care depends on multidisciplinary collaboration rather than new technology. Most patients with excess cortisol first present in primary care, diabetes, or hypertension clinics. When a clinician encounters treatment resistance beyond what poor medication adherence can explain, a timely DST can change care decisions [3, 4, 5, 86]. Point‐of‐Care Testing Maintaining testing at the point of care is essential. Once clinical suspicion develops and all routes of exogenous glucocorticoid exposure—including oral, inhaled, topical, intra‐articular, and epidural formulations—are ruled out, the 1‐mg DST should be ordered alongside routine laboratory evaluations. The CATALYST protocol offers a highly practical framework: clinicians should exclude common causes of false‐positive results—such as oestrogen therapy, heavy alcohol consumption, and untreated sleep apnea—confirm adequate dexamethasone levels, and proceed to adrenal imaging only after biochemical confirmation is secured [11, 37]. Prompt review of results and direct communication with endocrinology services prevent delays in diagnosis [86, 87]. Joint pathways across disciplines establish parallel workflows between diabetes, cardiology, and endocrine services, reducing diagnostic uncertainty [53, 86, 87]. Multidisciplinary Collaboration Effective management necessitates collaboration between endocrinologists, diabetologists, cardiologists, and surgeons. Establishing consistent plans for medication de‐escalation and electrolyte monitoring helps avoid conflicting instructions from different specialists. Regular case reviews and clinical audits across teams ensure that hypercortisolism becomes a routine part of metabolic risk management rather than a niche endocrine issue [53, 86, 87, 88]. Any decision to initiate mifepristone or a steroidogenesis inhibitor should involve endocrinology, as these therapies require specialized interpretation of biochemical testing, careful titration, and structured monitoring for adrenal insufficiency, cortisol withdrawal syndrome, electrolyte disturbances, drug interactions, and treatment‐specific adverse effects. Patient Education Patient education is essential. Explaining that cortisol dysregulation exists on a spectrum, and that many mild cases are highly manageable, can significantly reduce anxiety and improve diagnostic adherence [86]. Providing straightforward educational materials that describe the testing process and the warning signs of adrenal insufficiency and cortisol withdrawal syndrome ensures patients remain informed and know exactly when to seek medical attention [86]. System Integration At the health‐system level, cortisol assessment can be incorporated into existing diabetes, hypertension, and adrenal‐incidentaloma workflows by using clear case‐finding criteria and standardized testing pathways. For adrenal incidentalomas specifically, all major guidelines recommend biochemical screening for autonomous cortisol secretion at the time of discovery, regardless of whether clinical signs of cortisol excess are present [4, 5]. Current endocrine guidelines support use of the 1‐mg overnight dexamethasone suppression test when autonomous cortisol secretion is suspected, particularly in patients with adrenal incidentalomas or clinical features compatible with hypercortisolism [4, 87, 89]. Embedding DST prompts into diabetes or hypertension order sets for selected high‐risk patients could help standardize testing and referral, though this approach has not yet been validated in outcomes‐based studies. Supporting this proactive approach, CATALYST found cortisol non‐suppression in approximately one‐quarter of patients with difficult‐to‐control T2D, with higher rates among patients requiring multiple antihypertensive medications [11]. Correctly identifying appropriate candidates for testing ultimately leads to better patient outcomes and improved health system efficiency. Integrated workflows between endocrine and cardiometabolic care teams can help ensure that cortisol assessment becomes a routine component of metabolic risk evaluation in appropriately selected patients [3, 4, 5, 53, 86, 87, 89]. Conclusion Hypercortisolism links endocrine disease with common metabolic conditions. Overt Cushing syndrome is uncommon, and confirmed endogenous hypercortisolism remains infrequent in unselected diabetes populations; however, abnormal cortisol suppression on screening DST is increasingly recognized in selected patients with difficult‐to‐control diabetes, resistant hypertension, and adrenal incidentalomas [5, 6, 7, 8, 10, 11, 13, 14, 15, 27]. Despite this growing recognition, hypercortisolism remains substantially underdiagnosed in routine clinical practice—a missed opportunity, given that even modest cortisol excess can worsen insulin resistance, increase arterial stiffness, and accelerate tissue breakdown [6, 10, 15, 20, 21, 27]. Evaluation for cortisol excess should be considered early when metabolic disease is refractory or atypical—for example, in cases of resistant hypertension, unexplained worsening glycemia, or an adrenal incidentaloma. The 1‐mg dexamethasone suppression test must be performed carefully and interpreted within the appropriate clinical context. This approach helps distinguish physiologic variation from autonomous secretion and guides subsequent decisions regarding further evaluation and treatment [3, 4, 5, 25, 26]. Modern therapeutic options make meaningful disease control achievable for many patients. Surgery remains the curative standard when a distinct lesion can be resected; when surgery is not feasible, not curative, or not aligned with patient preference, glucocorticoid‐receptor antagonists and steroidogenesis inhibitors serve as effective medical alternatives that reduce cortisol activity at the receptor level or lower cortisol production, respectively [57, 64, 65, 66, 68, 72, 74, 85]. In the CATALYST treatment phase, mifepristone significantly reduced HbA1c and improved weight and waist circumference in patients with T2D and screening‐detected hypercortisolism, providing the first randomized, placebo‐controlled evidence that targeting cortisol pathways can improve cardiometabolic outcomes in this setting [57]. However, these benefits must be interpreted alongside substantial treatment discontinuation and the fact that the study population was defined by screening positivity rather than universally confirmed Cushing syndrome [57]. Newer agents under investigation include relacorilant (Lifyorli), a selective glucocorticoid‐receptor modulator without anti‐progesterone activity that is FDA‐approved for platinum‐resistant ovarian cancer but remains investigational for endogenous hypercortisolism [66, 67]. A separate investigational approach involves SPI‐62, a selective 11β‐HSD1 inhibitor designed to reduce local cortisol activation in target tissues [90]. The CAPTAIN‐T2D trial (NCT07296484) is evaluating whether pathological cortisol signalling can be mitigated without disrupting normal cortisol activity, an approach that could offer greater precision and improved tolerability if successful [91]. System‐level changes are also important. Training non‐endocrinologists to recognize high‐risk phenotypes, simplifying access to point‐of‐care cortisol testing, and creating shared follow‐up pathways between primary care and endocrinology can successfully bring hypercortisolism into routine cardiometabolic care [86, 87, 88]. Ultimately, therapeutic progress must be measured not only by normalized laboratory values but by tangible improvements in patient well‐being, such as a reduced daily medication burden and enhanced functional status [53, 82, 83]. Through careful evaluation, targeted treatment, and ongoing multidisciplinary monitoring, hypercortisolism can be recognized and managed as a contributor to cardiometabolic risk [5, 10, 11]. Funding The author has nothing to report. Conflicts of Interest The author is a consultant and Investigator for Sparrow Pharmaceuticals and Los Angeles Institute for Metabolic Research, and receives research funding from Sparrow Pharmaceuticals.